Auracare Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 5.78%
- Profit Growth 28.62%
- Ebitda 8.18%
- Net Worth 45.80%
- Total Assets 5.25%
About Auracare Pharma
Auracare Pharma Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 August 2017 (Seven years and six months 21 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vinay Khandelwal, Gurmeet Jolly, and Shalu Khandelwal serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999GJ2017PTC098536
- Company No.
098536
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Aug 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Auracare Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinay Khandelwal  | Director | 02-Aug-2017 | Current |
| Gurmeet Jolly | Director | 02-Aug-2017 | Current |
| Shalu Khandelwal | Director | 30-Apr-2024 | Current |
Financial Performance of Auracare Pharma.
Auracare Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.78% increase. The company also saw a substantial improvement in profitability, with a 28.62% increase in profit. The company's net worth Soared by an impressive increase of 45.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Auracare Pharma?
In 2023, Auracare Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Viralii Life Sciences Private LimitedVinay Khandelwal is a mutual person
Aukea Life Sciences Private LimitedVinay Khandelwal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Auracare Pharma?
Unlock and access historical data on people associated with Auracare Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Auracare Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Auracare Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.